• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DFAN14A filed by Seer Inc.

    6/24/26 4:00:22 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    DFAN14A 1 dfan14a09076074_06242026.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    INFORMATION REQUIRED IN PROXY STATEMENT

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    (Amendment No. )

     

    Filed by the Registrant ☐

     

    Filed by a Party other than the Registrant ☒

     

    Check the appropriate box:

     

    ☐Preliminary Proxy Statement

     

    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐Definitive Proxy Statement

     

    ☒Definitive Additional Materials

     

    ☐Soliciting Material Under § 240.14a-12

      

    SEER, INC.

    (Name of Registrant as Specified In Its Charter)

     

    BRADLEY L. RADOFF

    THE RADOFF FAMILY FOUNDATION

    JEC II ASSOCIATES, LLC

    THE MOS TRUST

    MOS PTC, LLC

    MICHAEL TOROK

    HOWARD H. BERMAN

    JOSHUA S. HOROWITZ

    LUIS E. RINALDINI

    (Name of Persons(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒No fee required

     

    ☐Fee paid previously with preliminary materials

      

    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

    Bradley L. Radoff, Michael Torok and the other participants named herein (collectively, the “Radoff-JEC Group”) have filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of highly qualified director nominees at the 2026 annual meeting of stockholders of Seer, Inc., a Delaware corporation (the “Company”).

     

    On June 24, 2026, the Radoff-JEC Group issued the following press release:

     

    The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

     

    Believes New Independent Directors Are Needed to Correct the Board’s Misaligned Priorities and Prevent Further Value Destruction

     

    Reveals Seer’s Board Has Not Responded to the Radoff-JEC Group’s Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board’s Focus on its Own Entrenchment

     

     

    HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement.

     

     

     

     

     

    ·Seer’s Board of Directors (the “Board”) has destroyed value for stockholders while enriching Company insiders:
    oThe Company has posted a -97.0% share price decline since its December 2020 IPO.1
    oSeer has generated cumulative reported losses exceeding $465 million since its IPO.2
    oSeer has delivered virtually no revenue growth over the last three fiscal years, while investing over $160 million.3
    oThe Board has rewarded Chairman and CEO Omid Farokhzad, M.D. with nearly $37 million in cumulative compensation while a stockholder who purchased one share at the time of the IPO ($19.00) would be left with less than $0.63.4

     

    ·Seer has no plan to create stockholder value under Chairman and CEO Omid Farokhzad, M.D.:
    oDr. Farokhzad has destroyed more than $1 billion in investor capital across five separate companies, evidence supporting our belief that he is incapable of turning around Seer.5
    oThe strategic plan overseen by the Board anticipates Seer will not achieve profitability until 2031.6
    oThe Board rejected our three proposals to acquire Seer for premiums of 33% - 42% to its unaffected share price and a contingent value right – proposals which we believe provide substantially greater certainty of value creation than the Company’s current strategic plan – without even engaging with us.

     

    ·Seer’s Board has not responded to our proposal to settle this proxy contest:
    oOn June 15, 2026, we proposed to end our ongoing proxy contest in exchange for Seer adopting governance enhancements and conducting a tender offer for 20 million shares at $2.50 per share, which would be in line with the Board’s authorized buyback program and management’s statements that there is a “significant dislocation” in the Company’s share price.7
    oMore than a week later, the Board has still not responded to our settlement offer – which it requested in the first place – demonstrating that its priority is not delivering value or governance improvements for stockholders.
    oInstead of focusing on opportunities to maximize value for stockholders as Seer’s share price has consistently traded at a significant discount to net cash, the Board has diluted stockholders by repeatedly issuing large grants of restricted stock units and in-the-money options to Dr. Farokhzad and President and CFO David Horn.

     

    Vote FOR the Radoff-JEC Group’s Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Prevent Further Value Destruction

     

    Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar

     

    Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

     

    Visit www.SaratogaProxy.com/SEER to learn more.

     


    1 FactSet. Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial proposal to acquire the Company.

    2 The Company’s Form 10-K for the year ended December 31, 2025 filed on March 2, 2026.

    3 Company Form 10-K filings.

    4 Company proxy statements. FactSet; share price decline from December 4, 2020 through December 31, 2025.

    5 Seer, BIND Therapeutics, Inc., Selecta Biosciences, Inc., Tarveda Therapeutics, Inc. and Senti Biosciences Holdings, Inc.

    6 Company PRE 14A filed on October 10, 2025.

    7 On the Company’s Q1 2026 earnings call held on May 13, 2026, President and CFO David Horn said: “Our opportunistic share repurchase in the quarter reflect our continued belief that there is a significant dislocation in our share price.”

     

     

    Contacts

    Greg Lempel

    greg@fondrenlp.com

     

    or

     

    Saratoga Proxy Consulting LLC

    John Ferguson / Joseph Mills, 212-257-1311

    info@saratogaproxy.com

    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    5/4/2026$4.00Buy
    Canaccord Genuity
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Seer with a new price target

    Canaccord Genuity initiated coverage of Seer with a rating of Buy and set a new price target of $4.00

    5/4/26 8:35:45 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DFAN14A filed by Seer Inc.

    DFAN14A - Seer, Inc. (0001726445) (Subject)

    6/24/26 4:00:22 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DFAN14A filed by Seer Inc.

    DFAN14A - Seer, Inc. (0001726445) (Subject)

    6/15/26 5:00:18 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    6/15/26 4:58:20 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

    Believes New Independent Directors Are Needed to Correct the Board’s Misaligned Priorities and Prevent Further Value Destruction Reveals Seer’s Board Has Not Responded to the Radoff-JEC Group’s Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board's Focus on its Own Entrenchment Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today issued the following statement. This press release features multimedia. View the full release here: https://www.businesswir

    6/24/26 8:45:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening

    REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leader in deep, unbiased proteomics, today announced preliminary data presented at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference demonstrating the potential of the Proteograph® Product Suite to enable AI-driven approaches for multi-cancer screening. The findings were presented by Sang-Won Lee, Ph.D., Professor at Korea University and Chief Executive Officer of TargetX, and Jaewoo Kang, Ph.D., Professor at Korea University and Chief Executive Officer of AIGEN Sciences, during the Seer Breakfast Symposium on June 1 in San Diego. "By incorporating the Proteograph platform into our p

    6/22/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction

    Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today issued the following statement: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615188856/en/Source: FactSet; total stockholder return graph from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group's submission of its initial non-binding proposal to acquire the Company. "When Seer filed its proxy statement, the Board issued a 4,000-word letter t

    6/15/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/21/26 5:12:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:20:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Bazarko Anthony R.

    3 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:19:02 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign

    REDWOOD CITY, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company") today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting. The Board recommends that stockholders vote "FOR" the election of Seer's seven highly qualified nominees on the BLUE proxy card. The full text of the letter follows: Dear Fellow Seer Stockholders, You have an important choice to make regarding the future of Seer at our upcoming Ann

    6/15/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

    REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo

    5/13/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

    Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer's Proteograph® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced the appointment of Anthony Bazarko as Chief Commercial Officer. Mr. Bazarko brings more than two decades of commercial leadership experience across the life sciences, diagnostics, and biotechnology industries, with a demonstrated track record of driving revenue growth, building high-performing teams, and leading global go-to-market strategies. Mr. Bazarko joins Seer from

    5/4/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials